Pilot Trial of Homebound Stem Cell Transplantation
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 3/6/2019 |
| Start Date: | January 2016 |
| End Date: | January 2020 |
In this study, the investigators plan to see what happens when a person receives care in the
home setting. They want to find out if caring for a patient who has been treated with an ASCT
in the home setting is feasible. They want to find out what effects good and/or bad this will
have on the patient's recovery and treatment after ASCT. Studies in other institutions have
shown that providing care in the home setting after ASCT is safe, increases patient
satisfaction, and can decrease the risk of infection. It is our hope that this new approach
of providing care in the home setting will prove to be a feasible and safe option for
patients at Memorial Sloan Kettering Cancer Center (MSK).
home setting. They want to find out if caring for a patient who has been treated with an ASCT
in the home setting is feasible. They want to find out what effects good and/or bad this will
have on the patient's recovery and treatment after ASCT. Studies in other institutions have
shown that providing care in the home setting after ASCT is safe, increases patient
satisfaction, and can decrease the risk of infection. It is our hope that this new approach
of providing care in the home setting will prove to be a feasible and safe option for
patients at Memorial Sloan Kettering Cancer Center (MSK).
Inclusion Criteria:
- Diagnosis of Plasma cell dyscrasia
- Treatment plan including Autologous HSCT
- 18-80 years of age
- Appropriate homebound setting as defined by one of the following:
- Lodging at the MSK Residence.
- Staying at home or a "home equivalent" in any one of the zip codes as outlined in
the appendix. Home equivalent is defined as a residence which may or may not be
the primary residence of the patient.
- "Home equivalent" must pass the "Home Environment Screening Tool" for homebound
stem cell transplantation (not required for other MSK recognized lodging
facility).
- Adequate caregiver support as defined by:
- Single or multiple informal caregivers willing and able to provide 24 hour a day,
seven day a week supervision of the transplant recipient in their home or
"home-like" environment.
- Caregiver willing and able to fulfill the basic stem cell transplant caregiver
education requirements as determined by caregiver and healthcare team, including
social worker
- Have Wi-Fi connection
- Appropriate third party payer coverage for "Homebound Stem Cell Transplant Program"
- Both patient and caregiver willing to give and sign informed consent.
Exclusion Criteria:
- Patients with a documented active infection prior to starting their preparative
regimen. This includes grade 3 or higher viral, bacterial, or fungal infection.
- Uncontrolled arrhythmias
- Active or uncontrolled pulmonary disease
- Karnofsky Performance Scale (KPS) score <80
- Sorror Co-morbidity index > 4
- Creatinine clearance (calculated or measured) of < 50 cc/minute
- Inability of patient or caregiver to speak or read English (we currently do not have
the manpower to translate nor staff a multilingual homebound stem cell transplant
program with adequate educational materials).
- Inadequate housing arrangements
- Inadequate caregiver arrangements
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Heather Landau, MD
Phone: 212-639-8808
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
